BioCentury
ARTICLE | Finance

Following its blueprint

Why Nextech co-led a $94M series B for synthetic lethality play Ideaya

March 16, 2018 12:20 AM UTC

Ideaya Biosciences Inc.’s goal of developing treatments for genomically defined subsets of cancer patients led Nextech Invest to co-lead the company’s $94 million series B round.

Nextech, 6 Dimensions Capital, BVF Partners and Perceptive Advisors led the untranched round, joined by fellow new investors GV, Roche Venture Fund, Boxer Capital of the Tavistock Group, and Driehaus Capital. Also participating were existing investors 5AM Ventures, Canaan Partners, Celgene Corp. (NASDAQ:CELG), WuXi Healthcare Ventures and Alexandria Venture Investments...

BCIQ Company Profiles

Ideaya Biosciences Inc.

BCIQ Target Profiles

Aryl hydrocarbon receptor